Emily
Editor, Senior Moderator
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415166/
Moideen S, Thomas R, Suresh Kumar PN, Uvais NA, Ul Haq Katshu MZ. Psychosis in a patient with anti-NMDA-receptor antibodies experiencing significant stress related to COVID-19. Brain Behav Immun Health. 2020;7:100125. doi:10.1016/j.bbih.2020.100125
Letter to the Editor
The scale of the impact of COVID-19 pandemic on most aspects of day-to-day life is like never seen before. Not surprisingly, it is leading to significant psychological stress among general population, vulnerable communities, and particularly health care workers (Sani et al., 2020). There are reports of new-onset psychiatric symptoms and exacerbation of pre-existing psychiatric conditions associated with the pandemic related stress coming from across the globe (Majadas et al., 2020). Moreover, there is emerging evidence that the more severe the inflammatory response to SARS-CoV-2, worse the psychiatric outcome (Mazza et al., 2020). This is the first report of new-onset psychosis in a patient with anti-NMDA-receptor antibodies experiencing significant stress related to COVID-19 pandemic.
A 17-year-old boy with no significant past medical or psychiatric history presented with 2-weeks history of abrupt onset fever, urinary incontinence, slurred and incoherent speech, overactivity, mood incongruent crying, unprovoked anger outbursts and screaming, and reduced sleep. Prior to the onset of these symptoms, he was very distressed due to the potential risk of getting infected with SARS-CoV-2 and bullying by a neighbour who scared him that he would contract the infection from his father who had recently returned home from another state and was observing mandatory home quarantine. He was diagnosed with acute and transient psychotic disorder at a local hospital and prescribed oral olanzapine titrated up to 15 mg/day, but he showed no response...
Moideen S, Thomas R, Suresh Kumar PN, Uvais NA, Ul Haq Katshu MZ. Psychosis in a patient with anti-NMDA-receptor antibodies experiencing significant stress related to COVID-19. Brain Behav Immun Health. 2020;7:100125. doi:10.1016/j.bbih.2020.100125
Letter to the Editor
The scale of the impact of COVID-19 pandemic on most aspects of day-to-day life is like never seen before. Not surprisingly, it is leading to significant psychological stress among general population, vulnerable communities, and particularly health care workers (Sani et al., 2020). There are reports of new-onset psychiatric symptoms and exacerbation of pre-existing psychiatric conditions associated with the pandemic related stress coming from across the globe (Majadas et al., 2020). Moreover, there is emerging evidence that the more severe the inflammatory response to SARS-CoV-2, worse the psychiatric outcome (Mazza et al., 2020). This is the first report of new-onset psychosis in a patient with anti-NMDA-receptor antibodies experiencing significant stress related to COVID-19 pandemic.
A 17-year-old boy with no significant past medical or psychiatric history presented with 2-weeks history of abrupt onset fever, urinary incontinence, slurred and incoherent speech, overactivity, mood incongruent crying, unprovoked anger outbursts and screaming, and reduced sleep. Prior to the onset of these symptoms, he was very distressed due to the potential risk of getting infected with SARS-CoV-2 and bullying by a neighbour who scared him that he would contract the infection from his father who had recently returned home from another state and was observing mandatory home quarantine. He was diagnosed with acute and transient psychotic disorder at a local hospital and prescribed oral olanzapine titrated up to 15 mg/day, but he showed no response...